New Hope Emerging in the Treatment of PTSD in Women: Overcoming Suboptimal Outcomes

Pathophysiology and Pharmacologic Rationale of Emerging Agents for the Treatment of PTSD

MinuteCE®
ReachMD Healthcare Image
Media formats available:
Details
Episodes
Presenters
Comments
  • Overview

    Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 

    Joseph F. Goldberg, MD
    Clinical Professor of Psychiatry
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Dr. Goldberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Receives royalties: American Psychiatric Publishing, Cambridge University Press
    Consulting Fees: Genomind, Intra-Cellular Therapies, Luye Pharmaceuticals, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus
    Speakers' bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb

    Roger McIntyre, MD
    Professor of Psychiatry and Pharmacology
    University of Toronto
    Toronto, Canada

    Dr. McIntyre has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: CIHR/GACD/National Natural Science Foundation of China (NSFC), and the Milken Institute
    Consulting Fees: Abbvie, Alkermes, atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris
    CEO of Braxia Scientific Corp.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Recognize and overcome the unmet needs in post-traumatic stress disorder (PTSD), including failure to utilize validated guideline-recommended screening tools to diagnose PTSD in women 
    2. Incorporate PTSD treatment guidelines into clinical practice to ensure evidence-based management
    3. Evaluate the inadequacies and risks associated with off-label treatments for PTSD
    4. Explain the link between the pathophysiology of PTSD and the pharmacological rationale for treatment
    5. Educate on the new and emerging therapies for PTSD and how they fit into the clinical management  
  • Target Audience

    This activity has been designed to meet the educational needs of ob-gyns, primary care physicians, and psychiatrists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with post-traumatic stress disorder (PTSD).

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 contact hour/0.1 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-120-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).  

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME, LLC employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Otsuka America Pharmaceutical Inc.  

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We're glad to see you're enjoying MedEd On The Go…
but how about a more personalized experience?

Register for free